Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05099549 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers
A Phase 1 study, sponsored by NKGen Biotech.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT05099549 is a Phase 1 study that was terminated before completion, run by NKGen Biotech. The registered enrollment target is 11 participants.
The verdict
NCT05099549, a Phase 1 study, was terminated before completion, sponsored by NKGen Biotech.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.
Interventions
- BIOLOGICAL SNK01
- DRUG AFM24
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2021-11-03 |
| Est. Completion | 2023-09-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05099549
The ClinicalTrials.gov registry entry for NCT05099549 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NKGen Biotech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SNK01 is the first listed.
NCT05099549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05099549 about?
NCT05099549 is a clinical study titled "Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers". This is an open-label, multi-center study to evaluate the safety, tolerability, and anti-tumor activity of SNK01 in combination with AFM24 in subjects with advanced or metastatic EGFR-expressing cancers.
What is the current status of trial NCT05099549?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2021-11-03. Estimated completion is 2023-09-21.
What interventions are being tested in trial NCT05099549?
The interventions under investigation include: SNK01 (BIOLOGICAL), AFM24 (DRUG).
Who is sponsoring clinical trial NCT05099549?
This trial is sponsored by NKGen Biotech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.